Prostaglandins and aminoglycoside nephrotoxicity
The role of prostaglandins in the development of aminoglycoside-induced acute renal failure was studied in CD-COBS rats (200 to 250 g). The animals were treated with gentamicin (80 mg/kg), acetylsalicylic acid (ASA, 100 or 200 mg/kg), or both drugs or saline for 5 or 10 days. Renal function was stud...
Saved in:
Published in | Toxicology and applied pharmacology Vol. 78; no. 3; p. 386 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
01.05.1985
|
Subjects | |
Online Access | Get more information |
Cover
Loading…
Abstract | The role of prostaglandins in the development of aminoglycoside-induced acute renal failure was studied in CD-COBS rats (200 to 250 g). The animals were treated with gentamicin (80 mg/kg), acetylsalicylic acid (ASA, 100 or 200 mg/kg), or both drugs or saline for 5 or 10 days. Renal function was studied measuring creatinine clearance, blood urea nitrogen (BUN), and serum electrolytes, urine osmolality, and maximal urinary concentrating capacity after water deprivation and vasopressin administration. Gentamicin toxicity on the proximal tubule was evaluated by measuring urinary excretion of the lysosomal enzyme N-acetylglucosaminidase (NAG). Renal prostaglandin (PG) production was evaluated measuring the concentration of PGE2, PGD2, PGF2 alpha, 6-keto-PGF1 alpha, and thromboxane B2 (TXB2) in whole renal homogenate after a 15-min incubation at 37 degrees C using gas chromatography-mass spectrometry. Gentamicin alone reduced the glomerular filtration rate (GFR) 20 to 30% after 5 and 10 days of treatment. Combination with ASA potentiated the toxic effect of the aminoglycoside after 10 but not after 5 days of treatment. Similarly, gentamicin reduced the urinary concentrating capacity and addition of ASA worsened the effects. Gentamicin markedly increased NAG excretion but this effect was reduced by ASA, probably as a result of lysosomal stabilization. ASA alone inhibited the production of prostaglandins in renal tissue by 70 to 90% after single or multiple doses. The animals treated with gentamicin alone presented a significant, specific increase in PGE2 production after 10 days of treatment but this increase did not occur when the two compounds were given together. Since PGE2 has a vasodilatory effect in the kidney these results suggest that it may play a specific role in maintaining normal renal blood flow and GFR during the development of aminoglycoside nephrotoxicity. The inhibition of prostaglandin production by nonsteroid anti-inflammatory drugs prevents this compensatory mechanism and worsens the renal damage. |
---|---|
AbstractList | The role of prostaglandins in the development of aminoglycoside-induced acute renal failure was studied in CD-COBS rats (200 to 250 g). The animals were treated with gentamicin (80 mg/kg), acetylsalicylic acid (ASA, 100 or 200 mg/kg), or both drugs or saline for 5 or 10 days. Renal function was studied measuring creatinine clearance, blood urea nitrogen (BUN), and serum electrolytes, urine osmolality, and maximal urinary concentrating capacity after water deprivation and vasopressin administration. Gentamicin toxicity on the proximal tubule was evaluated by measuring urinary excretion of the lysosomal enzyme N-acetylglucosaminidase (NAG). Renal prostaglandin (PG) production was evaluated measuring the concentration of PGE2, PGD2, PGF2 alpha, 6-keto-PGF1 alpha, and thromboxane B2 (TXB2) in whole renal homogenate after a 15-min incubation at 37 degrees C using gas chromatography-mass spectrometry. Gentamicin alone reduced the glomerular filtration rate (GFR) 20 to 30% after 5 and 10 days of treatment. Combination with ASA potentiated the toxic effect of the aminoglycoside after 10 but not after 5 days of treatment. Similarly, gentamicin reduced the urinary concentrating capacity and addition of ASA worsened the effects. Gentamicin markedly increased NAG excretion but this effect was reduced by ASA, probably as a result of lysosomal stabilization. ASA alone inhibited the production of prostaglandins in renal tissue by 70 to 90% after single or multiple doses. The animals treated with gentamicin alone presented a significant, specific increase in PGE2 production after 10 days of treatment but this increase did not occur when the two compounds were given together. Since PGE2 has a vasodilatory effect in the kidney these results suggest that it may play a specific role in maintaining normal renal blood flow and GFR during the development of aminoglycoside nephrotoxicity. The inhibition of prostaglandin production by nonsteroid anti-inflammatory drugs prevents this compensatory mechanism and worsens the renal damage. |
Author | Gagliardi, L Bamonte, F Noseda, A Salmona, M Assael, B M Chiabrando, C |
Author_xml | – sequence: 1 givenname: B M surname: Assael fullname: Assael, B M – sequence: 2 givenname: C surname: Chiabrando fullname: Chiabrando, C – sequence: 3 givenname: L surname: Gagliardi fullname: Gagliardi, L – sequence: 4 givenname: A surname: Noseda fullname: Noseda, A – sequence: 5 givenname: F surname: Bamonte fullname: Bamonte, F – sequence: 6 givenname: M surname: Salmona fullname: Salmona, M |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/4049389$$D View this record in MEDLINE/PubMed |
BookMark | eNo9zk9LwzAYx_EcJnObvgOFHvUQ9-Rfmxxl-A8G86DgbaTJ0xlpk9JUsO_egcPTB76HH78lmcUUkZArBncMWLkGkIwC6I8brW4NcCmpmJHFfz4ny5y_AMBIyeZkLkEaoc2CwOuQ8mgPrY0-xFwcKWwXYjq0k0s5eCwi9p9DGtNPcGGcLshZY9uMlydX5P3x4W3zTLe7p5fN_ZY6ocuRMit4Bd6YulEVtxpZUyrnlUKGinuUNUNtmgo4cIfOlFXthKgao-Co83xFrv92---6Q7_vh9DZYdqfnvNfy3hGng |
CitedBy_id | crossref_primary_10_1038_ki_2010_337 crossref_primary_10_1128_AAC_43_5_1003 crossref_primary_10_1590_S0100_879X2004000700006 crossref_primary_10_1016_S0195_5616_88_50128_6 crossref_primary_10_1111_j_1476_4431_2005_00167_x crossref_primary_10_1007_s10620_006_3145_8 crossref_primary_10_1002_ppul_1047 crossref_primary_10_1177_20420986211041277 crossref_primary_10_1016_S0024_3205_98_00070_8 crossref_primary_10_1179_joc_2001_13_5_461 crossref_primary_10_1016_0306_3623_95_00049_6 crossref_primary_10_1002_jps_2600830419 crossref_primary_10_1080_00039896_1990_9940810 crossref_primary_10_1111_j_0265_0215_1998_00269_x |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM |
DOI | 10.1016/0041-008X(85)90244-3 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | no_fulltext_linktorsrc |
Discipline | Public Health Pharmacy, Therapeutics, & Pharmacology |
ExternalDocumentID | 4049389 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M .55 .GJ .HR .~1 0R~ 123 1B1 1RT 1~. 1~5 29Q 3O- 4.4 457 4G. 53G 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIKC AAIKJ AAKOC AALRI AAMNW AAOAW AAQFI AAQXK AAXKI AAXUO ABEFU ABFNM ABFRF ABFYP ABJNI ABLST ABMAC ABXDB ABZDS ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADFGL ADMUD AEBSH AEFWE AEKER AENEX AFFNX AFJKZ AFKWA AFTJW AFXIZ AGHFR AGUBO AGYEJ AHEUO AHHHB AIEXJ AIKHN AITUG AJOXV AKIFW AKRWK ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLECG BLXMC C45 CAG CGR COF CS3 CUY CVF DM4 EBS ECM EFBJH EIF EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-2 G-Q GBLVA HMT HVGLF HZ~ IHE J1W KCYFY KOM LG5 M33 M41 MO0 N9A NPM O-L O9- OAUVE OGGZJ OVD OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SDF SDG SDP SES SEW SPCBC SPT SSJ SSP SSZ T5K TEORI TWZ UHS WH7 WUQ X7M XJT XPP Y6R YCJ ZGI ZKB ZMT ZU3 ZXP ~G- ~KM |
ID | FETCH-LOGICAL-c386t-1a3270d99bf572a8e1f65cd55e1e52de4b1e89f70202cec967bc337f950c33cd2 |
ISSN | 0041-008X |
IngestDate | Sat Sep 28 08:42:06 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 3 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c386t-1a3270d99bf572a8e1f65cd55e1e52de4b1e89f70202cec967bc337f950c33cd2 |
PMID | 4049389 |
ParticipantIDs | pubmed_primary_4049389 |
PublicationCentury | 1900 |
PublicationDate | 1985-May |
PublicationDateYYYYMMDD | 1985-05-01 |
PublicationDate_xml | – month: 05 year: 1985 text: 1985-May |
PublicationDecade | 1980 |
PublicationPlace | United States |
PublicationPlace_xml | – name: United States |
PublicationTitle | Toxicology and applied pharmacology |
PublicationTitleAlternate | Toxicol Appl Pharmacol |
PublicationYear | 1985 |
SSID | ssj0009441 |
Score | 1.3855807 |
Snippet | The role of prostaglandins in the development of aminoglycoside-induced acute renal failure was studied in CD-COBS rats (200 to 250 g). The animals were... |
SourceID | pubmed |
SourceType | Index Database |
StartPage | 386 |
SubjectTerms | Analysis of Variance Animals Aspirin - pharmacology Blood Urea Nitrogen Body Weight - drug effects Creatinine - metabolism Drug Interactions Gas Chromatography-Mass Spectrometry Gentamicins - toxicity Glomerular Filtration Rate - drug effects Injections, Intraperitoneal Kidney Cortex - drug effects Kidney Cortex - metabolism Kidney Cortex - pathology Male Prostaglandins - biosynthesis Prostaglandins D - biosynthesis Prostaglandins D - urine Prostaglandins E - biosynthesis Prostaglandins E - urine Prostaglandins F - biosynthesis Prostaglandins F - urine Rats |
Title | Prostaglandins and aminoglycoside nephrotoxicity |
URI | https://www.ncbi.nlm.nih.gov/pubmed/4049389 |
Volume | 78 |
hasFullText | |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3dS-QwEA-nIggifqKnHnnw5ERzNm3TJI963CkHJ_uwwr5JkiZSONsF-3DeX3-TprttvQ_0XtqSsCHkNzudmc5vBqGjOM1trrQkvpgaAaEQRGiuCSi-zLoo0cL50MC3m-z6Nv06YZMuib1hl9T6o_n5R17J_6AKY4CrZ8m-Atn5ojAAz4AvXAFhuL4I45GnbKimC4fPdGnqrj4UZXX__clUvg_naWkBrKqufhSmqAdfcMd-rCvApFprdNqVsp4H2wFCFT7mX5728gEKBZ52mQ9jrVewncJLXcdoaBJoHwGrLnSaB96dYF1S30x1ppSAwTDpq04ueiKS9PRgEupb_6afQ6hgvhYY0YK9929EsDJI0v8JnPT0ocEtBScmCX2G_jn5rG52O7OAFrjwCvDGh3Fm1ZjTNLRSbPcx41TS7Hw-9kGwk3ZfK2i5Xe2Z89EYIeN1tNZ6D_giiMIGemPLTXQ8Cpg9neFxx6Z7PMPHeNRDcxOthhgtDtSzLRQN5QfDDQ_lBw_lZxvdfvk8_nRN2g4axAACNaEqiXmUS6kd47ESlrqMmZwxSy2Lc5tqaoV0HHyG2FgjM65NknAnWQR3k8c7aLGsSruLsDGGWkO9uwAGjZOaRTGXVEmhlXM820M74WTupqFMyl17ZG__NrGPVjpBO0BLDv6V9hBMvFq_a-D6BUvpTWE |
link.rule.ids | 783 |
linkProvider | National Library of Medicine |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prostaglandins+and+aminoglycoside+nephrotoxicity&rft.jtitle=Toxicology+and+applied+pharmacology&rft.au=Assael%2C+B+M&rft.au=Chiabrando%2C+C&rft.au=Gagliardi%2C+L&rft.au=Noseda%2C+A&rft.date=1985-05-01&rft.issn=0041-008X&rft.volume=78&rft.issue=3&rft.spage=386&rft_id=info:doi/10.1016%2F0041-008X%2885%2990244-3&rft_id=info%3Apmid%2F4049389&rft_id=info%3Apmid%2F4049389&rft.externalDocID=4049389 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0041-008X&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0041-008X&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0041-008X&client=summon |